Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.

Literature DB >> 8894580

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.

P C Fuchs¹, A L Barry, S D Brown, D L Sewell.

Abstract

The activity of the new fluoroquinolone trovafloxacin (CP-99,219) was compared with that of ciprofloxacin and ofloxacin against 517 bacterial isolates representing 50 different species. Against members of the family Enterobacteriaceae, all three drugs showed good in vitro activity. Against most anaerobic bacteria, Staphylococcus, Streptococcus, and Enterococcus species, trovafloxacin was four- to sixteenfold more active than ciprofloxacin. For disk diffusion testing, 10 micrograms trovafloxacin disks gave satisfactory results. Tentative criteria are proposed for use during clinical studies.

Entities: Chemical

Mesh：

Substances：

Year: 1996 PMID： 8894580 DOI： 10.1007/bf01691159

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

6 in total

1. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors: C M Metzler; R M DeHaan
Journal: J Infect Dis Date: 1974-12 Impact factor: 5.226

2. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors: G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

3. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.

Authors: R N Jones
Journal: Diagn Microbiol Infect Dis Date: 1994-11 Impact factor: 2.803

4. In vitro activity of the new fluoroquinolone CP-99,219.

Authors: H C Neu; N X Chin
Journal: Antimicrob Agents Chemother Date: 1994-11 Impact factor: 5.191

5. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors: B B Gooding; R N Jones
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

6. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

Authors: S K Spangler; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1994-10 Impact factor: 5.191

6 in total

1. Quality control limits for dilution and disk diffusion susceptibility tests of trovafloxacin against eight quality control strains.

Authors: P C Fuchs; A L Barry; S D Brown
Journal: J Clin Microbiol Date: 1998-02 Impact factor: 5.948

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.

1. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

2. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

3. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.

4. In vitro activity of the new fluoroquinolone CP-99,219.

5. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

6. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

1. Quality control limits for dilution and disk diffusion susceptibility tests of trovafloxacin against eight quality control strains.

2. The new fluoroquinolones: A critical review.

Review 3. Ofloxacin otic solution: a review of its use in the management of ear infections.

4. Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia.

5. Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.

Review 6. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.